Vir Biotechnology/$VIR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vir Biotechnology
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Ticker
$VIR
Sector
Primary listing
Employees
367
Headquarters
Website
VIR Metrics
BasicAdvanced
$1.6bn
-
-$3.14
1.70
-
Price and volume
Market cap
$1.6bn
Beta
1.7
52-week high
$11.66
52-week low
$4.16
Average daily volume
1.6m
Financial strength
Current ratio
7.11
Quick ratio
6.52
Long term debt to equity
10.659
Total debt to equity
11.76
Profitability
EBITDA (TTM)
-451.049
Gross margin (TTM)
-566.77%
Net profit margin (TTM)
-675.96%
Operating margin (TTM)
-703.49%
Effective tax rate (TTM)
-0.08%
Revenue per employee (TTM)
$180,000
Management effectiveness
Return on assets (TTM)
-24.68%
Return on equity (TTM)
-47.69%
Valuation
Price to revenue (TTM)
20.193
Price to book
1.86
Price to tangible book (TTM)
1.92
Price to free cash flow (TTM)
-2.941
Free cash flow yield (TTM)
-34.00%
Free cash flow per share (TTM)
-3.189
Growth
Revenue change (TTM)
213.96%
Earnings per share change (TTM)
-25.64%
3-year revenue growth (CAGR)
-47.25%
3-year earnings per share growth (CAGR)
42.70%
What the Analysts think about VIR
Analyst ratings (Buy, Hold, Sell) for Vir Biotechnology stock.
VIR Financial Performance
Revenues and expenses
VIR Earnings Performance
Company profitability
VIR News
AllArticlesVideos
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
Business Wire·1 week ago
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
Business Wire·1 month ago
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs